List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 15 studies with search of: glioblastoma AND imatinib
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Conditions: Glioblastoma Multiforme;   Astrocytoma
Intervention: Drug: Imatinib mesylate; hydroxyurea
2 Completed Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Condition: Recurrent Glioblastoma Multiforme (GBM)
Intervention: Drug: Imatinib mesylate, Hydroxyurea (Hydroxycarbamide, HU)
3 Completed Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Condition: Recurrent Glioblastoma Multiforme (GBM)
Intervention: Drug: Imatinib mesylate, Hydroxyurea (Hydroxycarbamide, HU)
4 Suspended Open-Label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
Condition: Glioblastoma
Intervention: Drug: imatinib mesylate
5 Active, not recruiting Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Imatinib Mesylate & Hydroxyurea
6 Active, not recruiting Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Gleevec, RAD001, and Hydroxyurea
7 Recruiting Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Zactima, Gleevec, Hydroxyurea
8 Active, not recruiting Ph II Imatinib Mesylate + Hydroxyurea in Treatment for Pts w Recurrent/Progressive Meningioma
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Imatinib Mesylate and Hydroxyurea
9 Completed Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: imatinib mesylate;   Other: pharmacological study;   Procedure: conventional surgery
10 Completed Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: hydroxyurea;   Drug: imatinib mesylate;   Drug: vatalanib
11 Active, not recruiting Imatinib Mesylate in Treating Patients With Gliomas
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: imatinib mesylate
12 Recruiting Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: imatinib mesylate;   Drug: temozolomide;   Other: pharmacological study
13 Completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Gastrointestinal Stromal Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: imatinib mesylate
14 Completed Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: imatinib mesylate
15 Recruiting A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Conditions: Anaplastic Astrocytoma;   Glioblastoma
Intervention: Drug: Sunitinib Malate

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services